

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): June 19, 2026

TANGO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39485
(Commission
File Number)

85-1195036
(IRS Employer
Identification No.)

201 Brookline Ave., Suite 901
Boston, MA
(Address of principal executive offices)

02215
(Zip code)

Registrant's telephone number, including area code: 857-320-4900

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	TNGX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 19, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to seven (7).

Effective June 19, 2026, the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size. Mr. Azelby will serve as a Class II director until his term expires at the 2029 annual meeting of stockholders at which time he will stand for election by the Company’s stockholders. The Board determined that Mr. Azelby is independent under the listing standards of The Nasdaq Stock Market. The Board also approved the appointment of Mr. Azelby as a member of the Compensation Committee of the Board (the “Compensation Committee”) and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), effective as of June 23, 2026.

In accordance with the Company’s compensation program for non-employee directors, Mr. Azelby will receive an equity award consisting of a stock option to purchase 35,910 shares of the Company’s common stock, par value \$0.001 per share (“Common Stock”) at an exercise price of \$27.97 per share and a restricted stock unit (“RSU”) award to acquire 5,740 shares of Common Stock. The: (i) option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant, provided, however, that all vesting will cease if Mr. Azelby ceases to serve on the Board and (ii) the RSU award will vest in three equal annual installments over three years from the date of grant; provided, however, that all vesting will cease if Mr. Azelby ceases to serve on the Board prior to any applicable vesting of the RSU Award. In accordance with the Company’s compensation program for non-employee directors, Mr. Azelby will also receive an annual retainer of \$45,000 for Board service, \$7,500 for Compensation Committee service and \$5,000 for NCG Committee service, each to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. The Company has entered into an indemnification agreement with Mr. Azelby in the same form as the indemnification agreements the Company has entered into with its other directors, which form has been filed with the Securities and Exchange Commission (the “SEC”).

Except as set forth above, there are no arrangements or understandings between Mr. Azelby and any other person pursuant to which Mr. Azelby was selected as a director of the Company, there are no family relationships between Mr. Azelby and any of the Company’s other directors or executive officers, and Mr. Azelby is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated by the SEC.

The Company issued a press release on June 22, 2026 announcing the appointment of Mr. Azelby to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated June 22, 2026.
104	Cover page interactive data file (embedded within the Inline XBRL document)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TANGO THERAPEUTICS, INC.

Dated: June 23, 2026

By: /s/ Matthew Gall
Name: Matthew Gall
Title: Chief Financial Officer



Tango Therapeutics Appoints Robert Azelby to Board of Directors

June 22, 2026

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with pancreatic cancer.

“As Tango continues to evolve from a research-led organization into a company positioned to bring vopimetostat to patients, we are thoughtfully strengthening our Board with leaders who have successfully guided innovative medicines through late-stage development, approval and commercialization,” said Malte Peters, MD, Chief Executive Officer of Tango Therapeutics. “Bob’s extensive operating and board experience across oncology and the broader biopharmaceutical industry will be invaluable as we work to advance vopimetostat towards the market and execute on our mission to transform care for patients with MTAP-deleted cancers.”

“I am excited to join Tango’s Board at such an important time for the company,” said Mr. Azelby. “Tango has built a compelling clinical-stage pipeline grounded in synthetic lethality, and vopimetostat represents a significant opportunity to transform care for patients with MTAP-deleted cancers. I look forward to working with Malte, the leadership team and my fellow directors as Tango advances its clinical and strategic priorities.”

Mr. Azelby is a biopharmaceutical executive and experienced public company director with more than 30 years of industry leadership spanning executive management, commercial strategy, oncology product launches and corporate governance. He served as President and Chief Executive Officer of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders, from October 2020 to February 2023. Previously, he was Chief Executive Officer of Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines, from June 2018 through its acquisition by H. Lundbeck in 2019. He also served as Executive Vice President and Chief Commercial Officer of Juno Therapeutics, Inc. from November 2015 through its acquisition by Celgene in 2018.

Earlier in his career, Mr. Azelby spent 15 years at Amgen Inc., one of the world’s leading biopharmaceutical companies, where he held progressively senior commercial leadership roles. He concluded his tenure there as Vice President and General Manager of Oncology, overseeing the commercial performance of Amgen’s \$6 billion oncology portfolio. He currently serves on the Boards of Directors of ADC Therapeutics, Autolus Therapeutics and Cardinal Health, Inc., and previously served on the boards of Terns Pharmaceuticals, Eliem Therapeutics, Alder BioPharmaceuticals, Chinook Therapeutics, Immunomedics, Clovis Oncology and Cascadian Therapeutics. Mr. Azelby earned a B.A. in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.

About Vopimetostat

Vopimetostat is a potentially best-in-class oral, once-daily, MTA-cooperative PRMT5 inhibitor designed to work selectively in cancer cells with MTAP deletion. MTAP deletions occur in 10–15% of all human cancers, including approximately 40% of pancreatic cancer and 15% of lung cancer. Vopimetostat is being evaluated as a monotherapy and in combination clinical studies.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding Forward-looking statements are not purely historical and may be accompanied by words such as “may,” “should,” “expect,” “intend,” “plan,” “will,” “goal,” “estimate,” “anticipate,” “believe,” “predict,” “designed,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: Dr. Peters’s and Mr. Azelby’s statements in this press release and statements regarding: the anticipated benefits and potential of vopimetostat, both as a monotherapy and in combination; the company’s ability to advance vopimetostat toward potential regulatory approval and commercialization; the expected contributions of Mr. Azelby to Tango’s Board of Directors; and Tango’s clinical development and strategic priorities.

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond Tango’s control, and actual results could differ materially from those expressed or implied by these statements. These risks and uncertainties include, among others, risks related to drug development, clinical trials, regulatory review and approval, commercialization, competition, financing and Tango’s ability to execute its business strategy. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

Investors:

Elizabeth Hickin
ehickin@tangotx.com

Media:

1AB
Amanda Lazaro
amanda@labmedia.com